Seven peptides go before the FDA on July 23–24. We email when the status of any of them actually moves — votes, briefing documents, final rules — plus the occasional licensed-access update. Plain English. Evidence first. No hype, no filler.
No daily noise. You hear from us when something actually moves — a committee vote, a posted briefing document, a final rule, or licensed-access news worth your attention.
What the decision means in practice: is it legal yet, what’s the evidence, what’s the realistic timeline. The same honesty as the site — unproven is called unproven.
When access opens, we point to licensed clinicians and regulated pharmacies. We never link to “research-use” sellers or the gray market.
The advisory committee finished two days of hearings. Here’s the scoreboard, what each vote does and doesn’t mean, and which peptides now move to the FDA’s rulemaking stage — the step that actually decides pharmacy access.
Reading time 3 min · every claim linked to the FDA record · no recommendations to buy or use anything.
Disclaimer. Peptide Docket is independent and not affiliated with the FDA. The peptides we cover are not FDA-approved. We do not sell, source, or facilitate the purchase of any peptide. Nothing on this page is medical advice.